Pancreatic Cancer Pipeline Insights Report 2024 (Updated) | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals

DelveInsight's, "Pancreatic Cancer Pipeline Insight 2024" report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pancreatic Cancer Pipeline Report
• DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
• The leading companies working in the Pancreatic Cancer Market include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
• Promising Pancreatic Cancer Pipeline Therapies in the various stages of development include Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
• September 2023: Golden Biotechnology Corporation announced a study of Phase 1 & 2 Clinical trials for Antroquinonol. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg TID and 300 mg TID, clinical treatment duration of 4 weeks, to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine.
• October 2023: Helix BioPharma Corporation announced a study of Phase 1 & 2 clinical trials for L-DOS47 and Doxorubicin. This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

Request a sample and discover the recent advances in Pancreatic Cancer Treatment Drugs @ Pancreatic Cancer Pipeline Report- https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Pancreatic Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pancreatic Cancer Overview
Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.

Find out more about Pancreatic Cancer Therapeutics Assessment @ Pancreatic Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Emerging Drugs Profile
• NIS793: Novartis AG
• Devimistat: Cornerstone Pharmaceuticals
• Masitinib: AB Science
• SBP-101: Panbela Therapeutics
• TAS-102: Taiho Pharmaceutical Co., Ltd.
• RAIN-32: Rain Oncology
• IMX-110: Immix Biopharma

Pancreatic Cancer Pipeline Therapeutics Assessment
There are approx. 290+ key companies which are developing the Pancreatic Cancer therapies. The Pancreatic Cancer companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, Novartis.

DelveInsight's Pancreatic Cancer Pipeline Report covers around 300+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pancreatic Cancer Pipeline Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Pancreatic Cancer Pipeline Therapies @ Pancreatic Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pancreatic Cancer Pipeline Report
• Coverage- Global
• Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
• Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Dive deep into rich insights for new drugs for Pancreatic Cancer Treatment, Visit @ Pancreatic Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Pamrevlumab: FibroGen
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Niraparib: Innovent Biologics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. CT041: CARsgen Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ONC 212: Oncoceutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Cancer Key Companies
21. Pancreatic Cancer Key Products
22. Pancreatic Cancer- Unmet Needs
23. Pancreatic Cancer- Market Drivers and Barriers
24. Pancreatic Cancer- Future Perspectives and Conclusion
25. Pancreatic Cancer Analyst Views
26. Pancreatic Cancer Key Companies
27. Appendix

For further information on the Pancreatic Cancer Pipeline therapeutics, reach out to Pancreatic Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://wanneroo-social.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-current-trends-and-future-prospects
https://visbn.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-corneal-healing-challenges
https://globalaffairs.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-in-treatment-and-growing-opportunities
https://snapped.mn.co/posts/navigating-the-persistent-epithelial-defects-market-current-trends-and-future-outlook
https://keywebco.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-unmet-needs-and-driving-innovation
https://machineintelligence.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://healthcaremarketresearch.edublogs.org/2024/03/13/navigating-the-landscape-of-persistent-epithelial-defects-market/
https://lgbtq-youth-chat.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges
https://sarabestexchange73158582.mn.co/posts/unveiling-the-persistent-epithelial-defects-market-a-comprehensive-outlook
https://network-1588972.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://rdd-rapter-gameing.mn.co/posts/persistent-epithelial-defects-market-outlook-addressing-the-unmet-needs-in-ocular-surface-disorders
https://rdd-rapter-gameing.mn.co/posts/persistent-epithelial-defects-market-outlook-addressing-the-unmet-needs-in-ocular-surface-disorders
https://vibe-3-0.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://brand-the-change.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://goodnow.mn.co/posts/exploring-the-persistent-epithelial-defects-market-a-niche-addressing-corneal-healing-challenges
https://lgbtq-youth-chat.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges-52580993
https://inspiremetoday.mn.co/posts/unraveling-the-persistent-epithelial-defects-market-a-comprehensive-perspective
https://shopsanity.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges
https://plenty-of-heathens.mn.co/posts/navigating-the-persistent-epithelial-defects-market-innovations-and-challenges
https://akademe.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-challenges-and-driving-innovation
https://naijases.mn.co/posts/navigating-the-persistent-epithelial-defects-market-innovations-and-challenges
https://gtribe.mn.co/posts/navigating-the-landscape-of-the-persistent-epithelial-defects-market
https://communenour.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-a-challenging-ophthalmic-condition
https://synkretic.mn.co/posts/navigating-the-landscape-of-the-persistent-epithelial-defects-market
https://lxgonline.mn.co/posts/exploring-the-persistent-epithelial-defects-market-a-comprehensive-analysis
https://regenerative-future.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-an-unmet-need
https://gamebook.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-challenges-and-opportunities
https://yizhanverse.mn.co/posts/understanding-the-persistent-epithelial-defects-market-a-glimpse-into-emerging-opportunities
https://clinalleve.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market
https://homes-for-homeless-children.mn.co/posts/52583828
https://weholdspace.mn.co/posts/52584896
https://boringbusiness.mn.co/members/16644151
https://businessboostier.mn.co/posts/52585024
https://amy-anisas-community.mn.co/posts/52585098
https://naitirabotu.mn.co/members/21957308
https://tech4goodwales.mn.co/posts/exploring-the-genital-herpes-market-outlook-trends-treatments-and-future-prospects
https://worldletinews.mn.co/members/20156129
https://local-urban-eats.mn.co/posts/52585609
https://wwwpreparatorianis.mn.co/posts/52585907
https://shaunbook.mn.co/posts/genital-herpes-market-outlook-advancements-and-challenges-ahead
https://playhq.mn.co/posts/52587238
https://linkasia.mn.co/posts/52587360
https://indicate.mn.co/posts/52587525
https://naijases.mn.co/posts/navigating-the-genital-herpes-market-current-trends-and-future-outlook
https://aeros.mn.co/posts/52587883
https://itravel.mn.co/members/20248979
https://churecipe.mn.co/posts/52588055
https://www-network-aus-au.mn.co/posts/genital-herpes-market-outlook-trends-treatments-and-future-prospects
https://mossfon.mn.co/posts/52588854
https://together.mn.co/posts/52589078
https://bipolarjungle.mn.co/posts/52589178
https://create-lifestyle.mn.co/posts/52589248
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/52589494
https://cic-mun.mn.co/posts/52589598
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/52589778

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website- https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.